AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05411731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy
Description: The study group (group B) who will receive Modified constraint induced movement therapy for 3 hrs. a day 12 hrs. a week in addition to the same exercise program given to the control group for 10 weeks.
Study NCT04844853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalography
Description: 128-channel electroencephalography
Study NCT04844853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tactile stimulation
Description: Vibrotactile sequence on the forearm
Study NCT04844853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Network task (computerized)
Description: Computer-based game challenging orienting and executive attention. The subject must chose which side an animal is going, using left and right buttons, depending on the validity of a cue and the congruency of flankers.
Study NCT04844853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Head-toes-knees-schoulders
Description: Following motor commands such as touch your head when they are congruent or incongruent.
Study NCT04844853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laby 5-12
Description: Test of motor planning using labyrinths
Study NCT04844853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-ABC 2
Description: Test of motor functions using various subtests of gross and fine motor function.
Study NCT04844853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroop animals
Description: Stroop test for preK children using animals instead of words
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab by IV route, per 28 days cycle - Cycle1: 10 mg/kg on days 1, 8, 15, and 22. Cycles 2 to 12: 10 mg/kg on days 1 and 15. From cycle 13: 10 mg/kg on day 1.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide by oral route, per 28 days cycle - 25 mg daily on days 1-21.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib sub-cutaneous, per 28 days cycle - Cycles 1 to 12: 1.3 mg/m2 on days 1, 8, 15. Cycles 13-18: 1.3 mg/m2 on days 1, 15.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
Study NCT04751877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by oral route, per 28 days cycle - 20 mg daily on days 1, 8, 15 and 22.
Study NCT04903795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hEGFRvIII-CD3 (BRiTE)
Description: Bispecific T cell engager possessing one effector binding arm specific for the epsilon subunit of CD3 (a signaling molecule complex associated with the T cell receptor on T cells) while the opposing target-binding arm is directed against the hEGFRvIII epitope that is differentially expressed on the surface of tumor cells
Study NCT06432504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeine content
Description: Participants will drink the same volume of coffee with different amounts of caffeine.
Study NCT05189028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin
Description: Neoadjuvant chemotherapy:gemcitabine and cisplatin
Study NCT05189028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin
Description: Neoadjuvant chemotherapy:gemcitabine and cisplatin
Study NCT06332105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glytactin
Description: Glycomacropeptide based protein substitute for dietary treatment of PKU
Study NCT06332105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-AA
Description: Amino acid based protein substitute for dietary treatment of PKU
Study NCT06474403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard Sugarbecker's operation
Description: Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
Study NCT06474403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: modified Sugarbecker's operation
Description: Eligible candidates who have developed parastomal hernias following stoma creation and consented to the study will undergo laparoscopic TEP repair. The procedure involves an initial unilateral transrectal incision followed by the creation of an preperitoneal or retro-rectus space where a mesh is positioned to reinforce the abdominal wall and the stoma. Also it will has was formed oblique hernia canal. The operative and postoperative outcomes of these patients will be studied in comparison with control group treated with the traditional Sugabecker's operation.
Study NCT05098847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Sintilimab will be administered at 200 mg i.v. every 3 weeks.
Study NCT05098847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Sintilimab plus lenvatinib will be initiated on day 14 after cryoablation. Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study NCT05098847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation treatment starts at day 0. Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study NCT05713565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital care solution for patients with Coronary Artery Disease
Description: A digital care solution that provides remote patient monitoring and a patient support program specifically developed for CAD patients. The digital care solution empowers self-assessment of CAD symptoms as well as positive lifestyle change by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
Study NCT05713565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care for patients with Coronary Artery Disease
Description: Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
Study NCT05713565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for patients with Coronary Artery Disease
Description: Follow-up and continuous care as usual in outpatient care (i.e., Standard of Care). The participants in the Standard of Care - control group will also receive an information leaflet about relevant lifestyle modifications for CAD.
Study NCT04880148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thyme and Honey-based oral spray
Description: 4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
Study NCT04880148 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral spray
Description: 4 X Sprays in the oral cavity before, immediately after and 6 hours following the radiotherapy session
Study NCT06287983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Sample Spondylitis Exercise Program
Description: The Sample Spondylitis Exercise Program recommended by the Spondylitis Association of America will be translated into Turkish and each exercise will be applied in 3\*10 sets. The exercise program will be applied to both groups, 3 sessions a week for 60 minutes for 6 weeks.
Study NCT06047353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: Motivational Enhancement Therapy (MET) is based on the principles of motivational interviewing and is designed to promote self-efficacy and maximize behavioral change. MET will be given via phone and/or in person (approximately 30 minutes) at baseline, week 1, week 2, week 4, and week 8.
Study NCT06047353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) therapy
Description: Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
Study NCT04854382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored information
Description: Tailored information about coronavirus for patients with chronic kidney disease by information videos followed by a teach back procedure
Study NCT05316506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anticipated Discomfort Language
Description: This language involves pain descriptors provided from physician to patient during procedure.
Study NCT05316506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Objective Descriptive Language
Description: This language involves neutral/objective descriptors provided from physician to patients during procedure.
Study NCT05469451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
Study NCT05469451 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy
Description: Irradiated with a low power density laser of 940 (nm), 100 megawatt, which will be calibrated and the result of the calibration will be checked with the use of the power meter. The equipment used will be a diode laser (BIOLASE™), the area to be irradiated will be the anterior segment of the lower arch, each tooth will be irradiated for a time of 10 seconds on the vestibular surfaces of the teeth and 10 seconds on the lingual surfaces of the teeth, both at gingival level and at apical level in scanning mode.
Study NCT05630326 — intervention group
Intervention type: OTHER
Intervention: comparing, prevalence
Description: Comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
Study NCT05630326 — intervention group
Intervention type: OTHER
Intervention: assessment
Description: comparing infants with UTIs caused by ESBL organism, or non ESBL organism.
Study NCT04735146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Participants in the experimental group will undergo the adapted physical activity program that will be co-designed during phase I of the study.~The 6-week program is aimed at improving the quality of life; increase the physical activity levels according to recommended guidelines; improving body awareness through an educational component; maintain and ameliorate the previous functions (for women previously active) and build the exercise background for sedentary women; increase physical fitness and functional capacity.
Study NCT05435417 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CBCT radiation
Description: CBCT scanning
Study NCT06047353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive Airway Pressure (PAP) therapy
Description: Positive Airway Pressure (PAP) therapy will be administered as per standard of care.
Study NCT06159140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: In vivo MRI
Study NCT05093296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
Study NCT05093296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
Study NCT05093296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Pill
Description: All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
Study NCT05093296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)
Study NCT05580341 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zerun HPV-9
Description: Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris), 0.5mL, three doses, 0,2,6 months
Study NCT05580341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL ®9
Description: GARDASIL®9 vaccine, 0.5mL, three doses, 0,2,6 months
Study NCT04369157 — intervention group
Intervention type: PROCEDURE
Intervention: Elective surgery
Description: Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.
Study NCT06166108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane (TAP) block in Abdominal hysterectomy
Description: Comparative evaluation of magnesium sulphate versus dexamethasone as an adjuvant to bupivacaine in ultrasound guided transversus abdominis plane block for Abdominal hysterectomy as postoperative analgesia.
Study NCT05630326 — intervention group
Intervention type: OTHER
Intervention: association
Description: comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
Study NCT05630326 — intervention group
Intervention type: OTHER
Intervention: evaluation
Description: comparing ESBLUTI with COVID-19 and ESBL UTI without COVID-19
Study NCT04947917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpotTM Tattoo Ink
Description: Ink injection
Study NCT05167591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug concentration measurement
Description: Measurement of paracetamol concentration in capillary, venous plasma and saliva samples after standard premedication with paracetamol
Study NCT04995861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block and IPACK block
Description: Peripheral nerve blocks
Study NCT06416696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 1. Radiotherapy: Both external beam and brachytherapy, with radiation therapy techniques, target delineation, prescribed doses, and organ-at-risk constraints following established guidelines.~2. Chemotherapy: The preferred regimen is cisplatin at a dose of 40mg/m\^2 administered intravenously once weekly for 5-6 cycles; for patients intolerant to cisplatin or with renal impairment, carboplatin (AUC=2) may be considered, also administered once weekly.~3. Toripalimab concurrent immunotherapy: Following the regimens of phase III RCTs such as JUPITER-02, JUPITER-06, CHOICE-01, NEOTORCH, and RENOTORCH, Toripalimab is administered at a fixed dose of 240mg per infusion, given intravenously once every 3 weeks for three doses.~4. The concurrent chemoradiotherapy and immunotherapy phase does not exceed 8 weeks in duration.
Study NCT03992443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUSA-081
Description: Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
Study NCT05450887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid Tablets（OCA）
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).
Study NCT05450887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA：13\~15 mg/kg/day
Study NCT05450887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA：13\~15 mg/kg/day
Study NCT05450887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：Once a day (QD) by mouth (PO).
Study NCT06366035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoVE4MUM mobile application
Description: LoVE4MUM is an innovative mobile application developed based on cognitive behavioral therapy and psychoeducation. The mobile application consist of 5 main modules which delivers information pertaining self-care, postpartum depression, handling negative thoughts, mood tracking and information for seeking help. The module consist of short notes, videos and worksheets for the participants to conduct.
Study NCT04914390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT regimen
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study NCT04914390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
Study NCT04914390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.
Study NCT04985812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67484703
Description: Participants will receive JNJ-67484703.
Study NCT04985812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to JNJ-67484703.
Study NCT05930665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin
Description: Cadonilimab 10mg/kg intravenous (IV) every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks + Carboplatin AUC 5 IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Cadonilimab 10mg/kg IV every 3 weeks + Bevacizumab 7.5mg/kg IV every 3 weeks
Study NCT06142721 — intervention group
Intervention type: OTHER
Intervention: 3D Gait Analysis
Description: 3D gait analysis was applied to children. Static, kinematic and kinetic walking parameters were evaluated
Study NCT04818190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sensory neurotization
Description: The donor nerve is a cutaneous nerve that is identified with the most inferior lateral perforator vessels. The nerve is then dissected for neurotization and divided at the level of the fascia where it is a pure sensory nerve. The recipient intercostal nerve is usually easily identified in the third intercostal space during the dissection of the internal mammary artery and vein. The anterior branch of the third intercostal nerve can usually be found at the junction of the inferior portion of the third rib and the sternum, approximately 80% of the time. The nerve is dissected and transected medially. It is then mobilized to give it the longest length possible in preparation for neurotization. Neurotization is performed by coapting the donor nerve to the third anterior intercostal nerve directly with a 9-0 nylon suture in standard fashion.
Study NCT05693285 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05217251 — intervention group
Intervention type: OTHER
Intervention: frontal alpha asymmetry in EEG
Description: frontal alpha asymmetry based on EEG monitoring of uterine contractions in the first stage of labor. The power spectra will be log-transformed and averaged across the frontal left (FL) channels (FP1, F3, F7) and frontal right (FR) channels (FP2, F4, F8). A higher power spectrum value indicates lower neural activity. Frontal asymmetry (FA) power scores are calculated as follows, FA = (FR-FL)/(FR+FL). A positive FA value shows greater neural activity in the left frontal lobe than right frontal neural activity (relative left frontal asymmetry), while its negative value shows oppositely.
Study NCT05423600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BES + TS
Description: Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
Study NCT05423600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: BES+sham TS
Description: Blood Flow Restriction Enhanced Neuromuscular Electrical Stimulation (BES) sham treatment plus transspinal stimulation (TS) plus repetitive practice of task-specific activities, also known as massed practice (MP)
Study NCT06568237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56286
Description: TEV-56286 capsules administered orally
Study NCT06568237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally